Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Hepatic Radioembolization in Liver Dominant Metastatic Breast Cancer
NCT06860815Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and yttrium-90 resin microspheres in breast cancer, sponsored by City of Hope. Primary endpoint: CD8+ T cell infiltration in tumor microenvironment (TME) at day 42. Started Jan 2026; status: recruiting.
02
Drugs
cemiplimabyttrium-90 resin microspheres
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06860815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860815.